drugset / Trial / NCT04479917
Efficacy and Safety of TPN171H in the Patients With Erectile Dysfunction
Phase 2
Completed
255 enrolled
Vigonvita Life Sciences
Shanghai Institute of Materia Medica, Chinese Academy of Sciences · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This is an exploratory clinical study to presume the optimum usage and dosage for a therapeutic confirmatory study by evaluating the efficacy and safety of TPN171H 5mg, 10mg, 20mg or placebo administered orally in patients with erectile dysfunction. In conclusions, Patients with erectile dysfunction (ED) were administered placebo, TPN171H 5mg, 10mg or 20mg 30 minutes to 4 hours before sexual intercourse for 8 weeks.
Timeline
- Start
- 2020-07-23
- Primary completion
- 2021-07-26
- Completion
- 2021-07-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TPN171H | Unknown | 5 mg | Oral |
| Subject | TPN171H | Unknown | 10 mg | Oral |
| Subject | TPN171H | Unknown | 20 mg | Oral |